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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 94, Revision 1 
(FGE.94Rev1): 
Consideration of aliphatic amines and amides evaluated in an addendum to 
the group of aliphatic and aromatic amines and amides evaluated by the 
JECFA (68th meeting)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to consider evaluations of flavouring substances assessed since 
2000 by the Joint FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide 
whether further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. 
The present consideration concerns a group of 12 aliphatic amines and amides evaluated by the 
JECFA at the 68th meeting in 2007. This revision of the consideration is made due to additional 
toxicity data available for two substances, N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide  
[FL-no: 16.095] and N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111]. The 
substances were evaluated through a stepwise approach that integrates information on structure-
activity relationships, intake from current uses, toxicological threshold of concern and available data 
on metabolism and toxicity. The Panel agrees with the application of the Procedure as performed by 
the JECFA for 11 of the substances considered in this FGE and agrees with the JECFA conclusion, 
“No safety concern at estimated levels of intake as flavouring substances” based on the MSDI 
                                                     
 
1  On request from the European Commission, Question No EFSA-Q-2011-01120 and EFSA-Q-2012-00079, adopted on 24 
May 2012. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Leon Brimer, Laurence Castle, Karl-Heinz Engel, Roland 
Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude Lhuguenot, 
Daniel Marzin, Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Maria de Fatima Tavares Pocas, Fidel 
Toldra, Detlef Wölfle. Correspondence: cef@efsa.europa.eu. 
3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Leon Brimer, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik 
Frandsen, Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, 
Karin Nørby, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard Nielsen for the preparatory work on 
this scientific opinion. 
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approach. For one substance [FL-no: 16.090] additional toxicity data are still needed before the 
evaluation can be finalised. Besides the safety assessment of these flavouring substances, the 
specifications for the materials of commerce have also been considered and for one substance, [FL-no: 
16.090], the composition of the stereoisomeric mixture has to be specified. 
© European Food Safety Authority, 2012 
KEY WORDS 
JECFA 68th meeting, food safety, flavourings, aliphatic amines, aliphatic amides. 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000. These flavouring substances are listed in the Register, which was adopted by 
Commission Decision 1999/217/EC and its consecutive amendments. 
The consideration deals with 12 aliphatic amines and amides [FL-no: 16.090, 16.095, 16.098, 16.099, 
16.100, 16.101, 16.102, 16.103, 16.104, 16.105, 16.111 and 17.035], which are in the Register and 
which were evaluated by the JECFA at its 68th meeting. 
The present revision is made due to additional toxicity data requested in the previous opinion have 
been provided for N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide [FL-no: 16.095] and N-[ 
(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111]. 
The Panel concluded that no supporting Flavouring Group Evaluation was available for the substances 
in the present FGE.  
Genotoxicity data from in vitro and in vivo studies were available for seven [FL-no: 16.090, 16.095, 
16.098, 16.099, 16.102, 16.103 and 16.111] of the flavouring substances and the results did not 
indicate any concern for genotoxicity of the substances in this flavouring group. 
In the previous version of FGE.94 the Panel concluded that it could agree with the way the application 
of the Procedure has been performed by the JECFA for nine substances. For three substances [FL-no: 
16.090, 16.095 and 16.111] no adequate NOAEL were available. New 90-day studies have now 
become available for [FL-no: 16.095 and 16.111] and NOAELs to provide adequate margins of safety 
can be derived. 
For 3-(3,4-Dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] the 
JECFA used a NOAEL from a 90-day study in rats for N-nonanoyl-4-hydroxy-3-methoxybenzylamide 
([FL-no: 16.006] considered in FGE.86) to provide an adequate margin of safety. However, the Panel 
considers this substance not sufficiently structurally related to [FL-no: 16.090] to be used as a 
supporting substance. 
Thus, for one substance [FL-no: 16.090] the Panel concluded that additional toxicity data are still 
needed before it can be evaluated as a flavouring substance. 
For 10 of the 12 substances, use levels have been provided by the Industry. Based on the use levels the 
mTAMDI figures calculated for nine substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.102, 
16.103, 16.104, 16.111 and 17.035] are above the threshold of concern for their structural classes. For 
these nine substances more reliable data are needed. On the basis of such data the flavouring 
substances should be reconsidered using the Procedure. For the remaining two substances [FL-no: 
16.100 and 16.101], use levels are needed to calculate the mTAMDIs in order to identify those 
flavouring substances that need more refined exposure assessment. 
In order to determine whether the conclusion for the 12 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications are available for 11 substances [FL-no: 16.095, 16.098, 16.099, 16.100, 16.101, 16.102, 
16.103, 16.104, 16.105, 16.111 and 17.035] of the 12 materials of commerce. For one substance [FL-
no: 16.090] information on the stereoisomerism has not been specified sufficiently.   
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Thus, for one of the substance [FL-no: 16.090] the Panel has reservations (additional toxicity data are 
needed and the composition of the stereoisomeric mixture has to be specified). 
For the remaining 11 substances [FL-no: 16.095, 16.098, 16.099, 16.100, 16.101, 16.102, 16.103, 
16.104, 16.105, 16.111 and 17.035] the Panel agrees with the JECFA conclusion “No safety concern 
at estimated levels of intake as flavouring substances” based on the MSDI approach. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a).  
Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the 
Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered 
by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is 
necessary. 
In the period 2000 - 2008, during its 55th, 57th, 59th, 61st, 63rd, 65th, 68th and 69th meetings, the JECFA 
evaluated about 1000 substances, which are in the EU Register. 
TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION 
The European Food Safety Authority (EFSA) is requested to consider the JECFA evaluations of 
flavouring substances assessed since 2000, and to decide whether no further evaluation is necessary, as 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a). These flavouring substances 
are listed in the Register which was adopted by Commission Decision 1999/217 EC (EC, 1999a) and 
its consecutive amendments. 
The evaluation programme was finalised at the end of 2009.  
After the finalisation of the evaluation programme, in their letters of the 6th October 2011 and 23rd 
December 2011, the Commission requested EFSA to carry out re-evaluation of the flavouring 
substances, N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide [FL-no: 16.095] and N-[ 
(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] based on additionally submitted 
data on toxicity, and depending on the outcome, to proceed to the evaluation of these flavouring 
substances through the Procedure, also according to Commission Regulation (EC) No 1565/2000 (EC, 
2000a).  
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. 
This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has 
been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the 
“JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be put through the EFSA Procedure. 
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The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006c). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended that 
the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (“Do the condition of 
use result in an intake greater than 1.5 microgram per day?”)” (JECFA, 1999b).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 microgram per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a 
possible genotoxic potential of the flavouring substances or of structurally related substances. 
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Generally, substances for which the Panel has concluded that there is an indication of genotoxic 
potential in vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are 
provided. Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated 
through the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE 
In FGE.94, which contains a group of 12 aliphatic amines and amides, the Panel considered that 
additional toxicity data were needed for three substances [FL-no: 16.090, 16.095 and 16.111] before 
they could be evaluated as flavouring substances, as no adequate toxicity study from which a no 
observed adverse effect level (NOAEL) could be established was available, neither on the substances 
nor on supporting substances. 
FGE Opinion adopted 
by EFSA 
Link No. of 
candidate 
substances 
FGE.94 23 September 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1338.htm 
 
12 
FGE.94Rev1 24 May 2012  12 
 
Additional toxicity data have now been provided for two substances [FL-no: 16.095 and 16.111]. The 
data provided are 90-day studies for both substances. Furthermore, new metabolism and genotoxicity 
data have been provided for [FL-no: 16.111]. 
Since the publication of FGE.94, information on the stereoisomeric composition has been provided by 
EFFA for three substances [FL-no: 16.090, 16.102 and 16.104] and ID tests and solubility in ethanol 
have been provided for two substances [FL-no: 16.100 and 16.101] (EFFA, 2010a). 
1. Presentation of the Substances in the JECFA Flavouring Group 
1.1. Description 
1.1.1. JECFA Status 
The JECFA has evaluated a group of 12 flavouring substances consisting of aliphatic and aromatic 
amines and amides at the 68th meeting (JECFA, 2007c). 
1.1.2. EFSA Considerations 
All of the JECFA evaluated substances are in the Register. This consideration therefore deals with 
these 12 substances. The Panel concluded that there are no supporting substances from other FGEs for 
the aliphatic amines and amides evaluated by the JECFA (JECFA, 2007c). 
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1.2. Isomers 
1.2.1. Status 
The following five substances [FL-no: 16.102, 16.103, 16.104, 16.105 and 16.111] have one or more 
chiral centres. Two substances can exist as geometrical isomers [FL-no: 16.090 and 16.095]. 
1.2.2. EFSA Considerations 
For one substance [FL-no: 16.090] the composition of the stereoisomeric mixture has to be specified. 
Adequate information on isomeric composition is available for the remaining substances. 
For the three stereoisomeric substances [FL-no: 16.095, 16.105 and 16.111], the CAS register number 
(CASrn) is considered to specify the stereoisomeric composition (Table 1). 
1.3. Specifications 
1.3.1. JECFA Status 
The JECFA specifications are available for all substances (JECFA, 2008c).  
1.3.2. EFSA Considerations 
The European Flavour Industry has submitted specifications for all 12 substances commercially used 
in Europe (Flavour Industry, 2007h; Flavour Industry, 2008b; Flavour Industry, 2006u; Flavour 
Industry, 2006v; Flavour Industry, 2004l; Flavour Industry, 2006z; EFFA, 2006x). Although the 
JECFA specifications are available, the specifications used in this consideration are those submitted by 
the Industry. See Table 1. 
Specifications including complete purity criteria and identity are available for 11 substances [FL-no: 
16.095, 16.098, 16.099, 16.100, 16.101, 16.102, 16.103, 16.104, 16.105, 16.111 and 17.035].  
The stereoisomeric composition has not been specified sufficiently for one substance [FL-no: 16.090] 
(see Section 1.2.2 and Table 1). 
2. Intake Estimations 
2.1. JECFA Status 
For all 12 substances evaluated by the JECFA intake data are available for the EU. 
2.2. EFSA Considerations 
For 10 JECFA evaluated substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.102, 16.103, 16.104, 
16.105, 16.111 and 17.035] normal and maximum use levels have been provided by the Flavour 
Industry in accordance with the Commission Regulation (EC) No 1565/2000 (Flavour Industry, 
2007h; Flavour Industry, 2008b; Flavour Industry, 2006u; Flavour Industry, 2006v; Flavour Industry, 
2004l; Flavour Industry, 2006z; EFFA, 2006x; EC, 2000a) (see Table 2.2.1). Based on the normal use 
levels, mTAMDI figures (see Table 2.2.2) can be calculated (for calculation of mTAMDI figures, see 
e.g. FGE.03, Annex II (EFSA, 2004d). 
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Table 2.2.1 Normal and Maximum use levels (mg/kg) available for JECFA evaluated substances in FGE.94 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
16.090 3 
10 
- 
- 
5 
10 
- 
- 
- 
- 
10 
20 
- 
- 
10 
50 
- 
- 
- 
- 
- 
- 
- 
- 
5 
20 
- 
- 
3 
20 
5 
25 
10 
30 
5 
10 
16.095 0,01 
0,05 
0,01 
0,05 
0,1 
0,5 
- 
- 
- 
- 
1 
5 
- 
- 
0,1 
0,5 
0,01 
0,05 
0,01 
0,05 
- 
- 
- 
- 
0,01 
0,05 
- 
- 
1 
5 
1 
5 
0,01 
0,05 
0,01 
0,05 
16.098 1 
3 
2 
4 
- 
- 
1 
3 
1 
3 
- 
- 
- 
- 
1 
2 
1 
3 
1 
3 
- 
- 
- 
- 
5 
10 
- 
- 
- 
- 
- 
- 
5 
10 
1 
3 
16.099 1 
3 
2 
4 
- 
- 
1 
3 
1 
3 
- 
- 
- 
- 
1 
2 
1 
3 
1 
3 
- 
- 
- 
- 
5 
10 
- 
- 
- 
- 
- 
- 
5 
10 
1 
3 
16.102 50 
200 
50 
200 
50 
200 
- 
- 
- 
- 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
16.103 50 
200 
50 
200 
50 
200 
- 
- 
- 
- 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
16.104 5 
15 
- 
- 
5 
15 
5 
15 
- 
- 
5 
15 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
5 
15 
- 
- 
5 
15 
5 
15 
5 
15 
- 
- 
16.105 - 
- 
5 
15 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
5 
15 
- 
- 
- 
- 
- 
- 
5 
15 
- 
- 
- 
- 
- 
- 
5 
15 
- 
- 
16.111 10 
300 
10 
200 
10 
150 
10 
200 
10 
200 
10 
200 
10 
50 
20 
200 
10 
100 
10 
100 
- 
- 
- 
- 
- 
- 
20 
300 
10 
50 
10 
400 
50 
350 
10 
200 
17.035 30 
100 
30 
100 
20 
100 
- 
- 
- 
- 
30 
100 
30 
100 
50 
300 
20 
200 
- 
- 
- 
- 
- 
- 
- 
- 
30 
200 
30 
200 
40 
300 
20 
100 
30 
100 
 
Table 2.2.2 Estimated intakes based on the MSDI- and the mTAMDI approach 
FL-no EU Register name MSDI – EU 
(μg/capita/day) 
MSDI – USA 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
16.102 2,3,4,5,6-Pentahydroxy-N-(2-
hydroxyethyl)-hexanamide 
24 13 27000 Class I 1800 
16.103 (2R)-2-Hydroxy-N-(2-
hydroxyethyl)propanamide 
24 10 27000 Class I 1800 
16.104 2-[(2-
Hydroxypropanoyl)amino]ethyl 
dihydrogen phosphate 
12 5 2700 Class I 1800 
16.105 2-[(2,3,4,5,6-
Pentahydroxyhexanoyl)amino]ethyl 
dihydrogen phosphate 
12 3 870 Class I 1800 
17.035 4-Amino-butyric acid 0.12 0.1 18000 Class I 1800 
16.090 3-(3,4-Dimethoxy-phenyl)-N-[2-
(3,4-dimethoxyphenyl)-ethyl]-
acrylamide 
1.2 1 3000 Class III 90 
16.095 N-3,7-Dimethyl-2,6-octadienyl 
cyclopropylcarboxamide 
61 31 380 Class III 90 
16.098 N-(1-Propylbutyl)-1,3-
benzodioxole-5-carboxamide 
0.012 0.1 470 Class III 90 
16.099 N-(2,4-Dimethoxy-benzyl)-N'-(2-
pyridin-2-yl-ethyl)-oxalamide 
0.012 0.2 470 Class III 90 
16.100 N1-(2-Methoxy-4-methylbenzyl)-
N2-(2-(5-methylpyridin-2-
yl)ethyl)oxalamide 
0.012 0.01 ND Class III 90 
16.101 N1-(2-Methoxy-4-methylbenzyl)-
N2-(2-(pyridin-2-
yl)ethyl)oxalamide 
0.012 0.01 ND Class III 90 
16.111 N-[(Ethoxycarbonyl)methyl]-p-
menthane-3-carboxamide 
37 34 7400 Class III 90 
ND: No intake data available 
3. Genotoxicity Data 
3.1. Genotoxicity Studies – Text Taken4 from the JECFA (JECFA, 2008b) 
In vitro and in vivo genotoxicity testing has been performed on six flavouring substances [FL-no: 
16.090, 16.098, 16.099, 16.102, 16.103 and 16.111] in this group. The results of these studies are 
summarized in Table 2.1 and described below.  
                                                     
 
4 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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In Vitro 
N-(Heptan-4-yl)benzo[d][1,3]dioxole-5-carboxamide ([FL-no: 16.098] N-(1-propylbutyl)-1,3-
benzodioxole-5-carboxamide), N-gluconyl ethanolamine ([FL-no: 16.102] 2,3,4,5,6-pentahydroxy-N-
(2-hydroxyethyl)-hexanamide), N-lactoyl ethanolamine ([FL-no: 16.103] (2R)-2-hydroxy-N-(2-
hydroxyethyl)propanamide) and N-[2-(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxycinnamic acid 
amide [FL-no: 16.090] 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide) were 
tested in Salmonella typhimurium TA98, TA100, TA102, TA1535 and TA1537 and Escherichia coli 
WP2uvrA at concentrations up to 5000 μg/plate, with and without S9 activation. There was no 
evidence of an increase in revertants (Uhde, 2004b; Verspeek-Rip, 2004a; Verspeek-Rip, 2004b; 
Zhang, 2004a).  
N1-(2,4-Dimethoxybenzyl)-N2-(2-(pyridin-2-yl)ethyl)-oxalamide ([FL-no: 16.099] N-(2,4-dimethoxy-
benzyl)-N'-(2-pyridin-2-yl-ethyl)-oxalamide) induced an increase in the number of revertants in S. 
typhimurium TA1535 in the absence (but not in the presence) of metabolic activation compared with 
control values; however, no dose–response was observed, and the mean number of revertants was 
reported to be below historical spontaneous reversion or negative control values. When tested under 
the conditions of the preincubation assay at concentrations of up to 5000 μg/plate, N1-(2,4-
dimethoxybenzyl)-N2-(2-(pyridin-2-yl)ethyl)-oxalamide [FL-no: 16.099] induced an increase in the 
number of revertants in S. typhimurium TA100 in the presence of metabolic activation, but only at a 
concentration of 62 μg/plate; no dose–response pattern was observed, and no significant increases in 
the number of revertants were reported in the absence of metabolic activation at concentrations of up 
to 5000 μg/plate. Moreover, N1-(2,4-dimethoxybenzyl)-N2-(2-(pyridin-2-yl)ethyl)-oxalamide [FL-no: 
16.099] consistently tested negative in several other strains of S. typhimurium (TA98 and TA1537) 
and in E. coli WP2uvrA in both the absence and presence of metabolic activation, in both plate 
incorporation and preincubation assays, at concentrations of up to 5000 μg/plate. Given the lack of a 
dose-dependent response, non-reproducibility of results and the fact that the number of revertants was 
below historical control values, it was concluded that N1-(2,4-dimethoxybenzyl)-N2-(2-(pyridin-2- 
yl)ethyl)-oxalamide [FL-no: 16.099] was non-mutagenic (Zhang, 2005a). 
N-[(Ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] induced a slight increase in 
the number of revertants in S. typhimurium TA100 and TA1535 in the absence of metabolic activation 
compared with control values; however, the increase was not statistically significant. In a set of 
confirmatory experiments, S. typhimurium TA100 and TA1535 were retested at concentrations of 0, 
2000, 3000, 4000 or 5000 μg/plate without metabolic activation. The study reported an increase in 
revertant colonies in strain TA1535 that was reproducible and, at the highest concentration tested, was 
significantly above in-house historical controls. The report concluded that N-
[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] was weakly mutagenic to 
TA1535 under the test conditions. In contrast, increases observed in the revertant colonies in S. 
typhimurium TA100, although statistically significant, were small and did not follow a dose–response 
pattern. Moreover, N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] 
consistently tested negative in several other strains of S. typhimurium (TA98 and TA1537) and in E. 
coli WP2uvrA in both the absence and presence of metabolic activation, at concentrations of up to 
5000 μg/plate (Thompson, 2005). 
N-(Heptan-4-yl)benzo[d][1,3]dioxole-5-carboxamide [FL-no: 16.098] and N1-(2,4-dimethoxybenzyl)-
N2-(2-(pyridin-2-yl)ethyl)-oxalamide [FL-no: 16.099] produced no evidence of genotoxicity at 0, 21, 
62, 190, 560, 1670 or 5000 μg/ml in standard chromosomal aberration assays in Chinese hamster 
ovary cells cultured with and without S9 metabolic activation (Zhang, 2004b; Zhang, 2005b). 
In Vivo 
In a standard mouse micronucleus bone marrow assay, groups of 21 male Swiss albino (CD-1) mice 
per dose were injected intraperitoneally with 0, 175, 350 or 700 mg N-(heptan-4-
yl)benzo[d][1,3]dioxole-5-carboxamide [FL-no: 16.098]/kg bw. At 24, 36 and 48 hours following 
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dose administration, seven mice from each group were killed, and their femoral bone marrow was 
harvested, fixed and stained. No statistically significant differences were observed in the number of 
polychromatic erythrocytes with micronuclei between the test groups and the negative control (Pucaj, 
2004a).  
In a standard mouse micronucleus bone marrow assay using the same protocol as described above, 
groups of 21 male Swiss albino (CD-1) mice per dose were injected intraperitoneally with 0, 200, 400 
or 800 mg N1-(2,4-dimethoxybenzyl)-N2-(2-(pyridin-2-yl)ethyl)oxalamide [FL-no: 16.099]/kg bw. At 
24, 36 and 48 hours following dose administration, seven mice from each group were killed, and their 
femoral bone marrow was harvested, fixed and stained. No statistically significant differences were 
observed in the number of polychromatic erythrocytes with micronuclei between the test groups and 
the negative control (Pucaj, 2004b).  
In a similar standard mouse micronucleus bone marrow assay, male NMRI BR mice (five per group) 
were administered aqueous N-gluconyl ethanolamine [FL-no: 16.102] at 0 (negative or positive 
control) or 2000 mg/kg bw via gavage. Femoral bone marrow was isolated at 24 or 48 hours post-
administration. Treatment and control mice showed no difference in the ratio of polychromatic to 
normochromatic erythrocytes. N-Gluconyl ethanolamine [FL-no: 16.102] showed no mutagenic 
potential in the mouse micronucleus assay (Buskens, 2004a).  
Employing the same standard mouse micronucleus bone marrow assay as used above, male NMRI BR 
mice (five per group) were administered aqueous N-lactoyl ethanolamine [FL-no: 16.103] at 0 
(negative or positive control) or 2000 mg/kg bw via gavage. Femoral bone marrow was isolated 24 or 
48 hours after administration. Treated and control mice showed no difference in the ratio of 
polychromatic to normochromatic erythrocytes. N-Lactoyl ethanolamine [FL-no: 16.103] showed no 
mutagenic potential in the mouse micronucleus assay (Buskens, 2004a). 
Conclusion on Genotoxicity 
On the weight of evidence, negative results were obtained with the flavouring agents of this group 
when tested in in vitro mutation assays in S. typhimurium and E. coli, as well as in mammalian cells. 
Negative results were also obtained in in vivo micronucleus assays. 
For a summary of in vitro / in vivo genotoxicity data considered by the ECFA, see Table 2.1. 
3.2. New Genotoxicity Study on [FL-no: 16.111]  
A Mouse Lymphoma Assay for [FL-no: 16.111] (Flanders, 2006) was submitted after the publication 
of FGE.94.  
The study was conducted according to an adequate design to assess the potential mutagenicity of the 
test material on the thymidine kinase, TK +/-, locus of the L5178Y mouse lymphoma cell line 
(Flanders, 2006). L5178Y TK +/- 3.7.2c mouse lymphoma cells (heterozygous at the thymidine kinase 
locus) were treated with the test material at eight dose levels, in duplicate, together with vehicle 
(solvent) and positive controls. The entire experiment was repeated to confirm the result of the first 
experiment. Four hours exposures were used both with and without activation in Experiment 1. In 
Experiment 2, the exposure time without activation was increased to 24 hours. The dose range of test 
material, plated for expression of mutant colonies, was selected following the results of a preliminary 
cytotoxicity test and was 42.03 to 672.5 μg/ml in the absence of metabolic activation and 84.06 to 
1008.75 μg/ml in the presence of metabolic activation for the first experiment For the second 
experiment the dose range plated for expression of mutant colonies was 10.51 to 504.38 μg/ml without 
metabolic activation and 42.03 to 672.5 μg/ml with metabolic activation. 
The maximum dose level used was limited by test material induced cytotoxicity. A precipitate of test 
material was observed at 1345 μg /ml during the course of the study. The vehicle (solvent) controls 
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had mutant frequency values that were considered acceptable for the L5178Y cell line at the TK +/- 
locus. The positive control materials induced marked increases in the mutant frequency indicating the 
satisfactory performance of the test and of the activity of the metabolising system.  
The test material did not induce any statistically significant or dose-related increases in the mutant 
frequency at any dose level, either with or without metabolic activation, in either the first or the 
second experiment incorporating dose levels that exhibited optimum levels of cytotoxicity.  
Study results are presented in Table 2.2. 
3.3. EFSA Considerations 
Genotoxicity data from in vitro studies are available for seven substances [FL-no: 16.090, 16.095, 
16.098, 16.099, 16.102, 16.103 and 16.111] and in vivo studies were available for four substances [FL-
no: 16.098, 16.099, 16.102 and 16.103] of the 12 flavouring substances evaluated by the JECFA. 
The Panel noted that conflicting positive results were obtained for N-(2,4-dimethoxy-benzyl)-N'-(2-
pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099] in the one study by (Zhang, 2005a) when tested in the 
S. typhimurim TA1535 and TA100. However, no dose–related response was observed, the positive 
results with TA1535 and TA100 were not reproducible and concomitantly, the tests with TA98 and 
TA1537 were consistently negative (JECFA, 2008b). The Panel concluded that the available data did 
not raise concern about genotoxicity in the Ames test. 
For the consideration in FGE.94 on N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide [FL-no: 
16.095] an additional genotoxicity study was provided by the Industry (Next Century Incorporated, 
2004) after the JECFA evaluated the substance at the 68th meeting (JECFA, 2007c). In this study, the 
substance was tested in a bacterial reverse mutation test using S. typhimurium strains TA97a, TA98, 
TA100, TA1535, and E. coli strain WP2uvra with and without metabolic activation. It was concluded 
to be negative for the induction of mutagenicity (see Table 2.3).  
N-[(Ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] did not induce gene 
mutations at the thymidine kinase locus in L5178Y cells in the Mouse Lymphoma Assay (Flanders, 
2006). 
Overall, the Panel considered the available data not to raise concern with respect to genotoxicity. 
4. In Vitro Hydrolysis Study on [FL-no: 16.111]  
The hydrolysis of N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] was 
studied in artificial pancreatic juice and rat liver homogenate (Poet et al., 2005). Based on the 
disappearance of the employed substrate, [FL-no: 16.111] was hydrolysed in artificial pancreatic juice 
with a half-life of 43 ± 14.7 min. and a first order loss rate (K) of 1.06 ± 0.426 hr-1.  In 20 fold-diluted 
liver homogenate the disappearance of [FL-no: 16.111] was considerably faster (half-life: 0.802 ± 
0.191 min.). However, the potential hydrolysis products p-menthane-3-carboxylic acid, glycine 
ethylester and glycine were only detected at trace levels. This indicates that the disappearance of [FL-
no: 16.111] under the employed in vitro-conditions is due to the hydrolysis of the ethyl ester bond 
rather than the hydrolysis of the amide bond.  
This stability of the amide bond is in agreement with data provided for N-benzonitrile-p-menthan-3-
carboxamide, [FL-no: 16.117]. This structurally related substance was not hydrolysed when incubated 
with pooled hepatic microsomes from male rats or male humans under conditions in which hydrolytic 
enzymes were shown to be active (Sipes and Kong, 2012). 
In conclusion, the Panel considers that the candidate substance [FL-no: 16.111] cannot be expected to 
be metabolized to innocuous products.  
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5. 90-Day Studies on [FL-no:16.095 and 16.111] 
90-day studies requested in the previous version of this FGE were submitted for [FL-no: 16.095 and 
16.111] by the Industry. 
5.1. 90-day dietary toxicity study in Crl:CD (SD) rats on N-3,7-dimethyl-2,6-octadienyl- 
cyclopropylcarboxamide [FL-no: 16.095] 
A 90-day dietary toxicity study followed by a 28-day recovery period was performed with N-3,7-
dimethyl-2,6-octadienyl cyclopropylcarboxamide [FL-no: 16.095] in rats (Bauter, 2011). The study 
was performed according to OECD guideline (TG 408) under GLP. The dose levels tested were 0, 11, 
110, and 1100 mg N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxyamide/kg diet, equal to mean 
daily exposures of 0, 0.7, 7.3, and 73.3 mg/kg bw/day in the male rats and of 0, 0.8, 8.1, and 80.1 
mg/kg bw/day in the female rats. Each test group consisted of 10 animals per sex. Recovery groups 
were included for the control and high dose groups as well. Clinical observations, functional 
observation battery and motor activity were recorded. The feed homogeneity was checked by dietary 
chemical analysis. Data on body weight and individual food consumption were collected throughout 
the in-life phase of the study. Blood samples were taken for complete haematological, clinical 
chemical and serological analyses. At study termination body weight, organ and tissue weights were 
recorded after macroscopical examination and complete histopathology was performed on the animals 
of the control and highest dose groups. No substance related effects were found implying that the 
highest dose group is the NOAEL of 1100 mg/kg diet which is equal to approximately 73 mg N-3,7-
dimethyl-2,6-octadienyl cyclopropylcarboxamide /kg bw/day in the male rats. 
5.2. 90-day oral (by gavage) toxicity study in Crl:CD (SD) rats on N-
[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] 
A 90-day oral toxicity study by gavage in Crl:CD (SD) rats followed by 14-day recovery period was 
performed with N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] 
(Kirkpatrick, 2011). The study was performed according to OECD guideline (TG 408) under GLP. 
The substance was administered at doses of 0, 25, 75, 225 and 675 mg N-[(ethoxycarbonyl)methyl]-p-
menthane-3-carboxamide/kg bw/day to 10 animals/sex/dose group via gavage. Recovery groups were 
included for the control and high dose groups. The following parameters were evaluated: daily clinical 
observation, weekly recording of individual body weight and food consumption while clinical 
chemistry, hematology, blood clotting parameters and urinalysis were done at study termination and at 
the end of the recovery period. A modified Irwin test, performed before start and on week 12 of the 
study, was conducted in order to evaluate any potential effect on the central nervous system. 
Ophtalmology examination was performed on week 1 and week 12 of the study. Complete necropsies 
were conducted on all animals and selected organs were weighted. Selected tissues were examined 
microscopically from all animals in the control and the 675 mg/kg bw/day groups at the primary 
necropsy. Kidney, liver, heart and gross lesions were examined microscopically from all animals at the 
scheduled necropsies. Sections of kidneys were also evaluated for presence of α-2-globulin by 
immunohistochemistry. Spermatogenic endpoints (motility, morphology and numbers) were evaluated 
for all males at the scheduled necropsies. 
Test substance related higher neutrophil (in males and females; m+f), monocyte (m), and white blood 
cell count (m+f) were observed in the high-dose group. These increases declined after the recovery 
period. Lower hematocrit values were seen at 225 and 675 mg/kg bw/day in the males but not in the 
females. However, lower hematocrit, accompanied by decrease in hemoglobin, red blood cell count, 
mean corpuscular volume and increase in red cell distribution width were observed after the recovery 
period in both sexes at 675 mg/kg/ bw/day.  
Higher serum creatinine (m+f), urea nitrogen (m+f), calcium (m), and triglycerides (m+f), and lower 
serum albumin/globulin ratios (m+f) and chloride levels (m+f) and higher total urine volume and 
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lower specific gravity were observed at 675 mg/kg bw/day in males and females. These changes were 
not present after the recovery period.  
At gross macroscopy, enlarged kidneys with rough surface were observed in one male and pale kidney 
was reported for one female rat at 675 mg/kg bw/day, which correlated with the histopathological 
observation of renal tubular degeneration. An increase in liver and kidney weight was observed in 
male and female rats at 675 mg/kg bw/day though this finding was no longer present after the recovery 
period.  
Test substance-related microscopic findings were noted in the kidney (tubular degeneration, and 
dilatation, interstitial fibrosis and tubular epithelium vacuolation) and the liver (periportal 
hepatocellular vacuolation and centrilobular hepatocellular hypertrophy) in both male and female rats 
and heart (increase in incidence of cardiomyopathy; females only) at 675 mg/kg bw/day. Furthermore, 
tubular hyaline droplets were observed in male kidney at all doses. However, this finding was not dose 
related and considered to correlate with the increase in male rat specific α-2µ-globulin observed at 
immunohistohemical investigation. Microscopic changes in the kidney, liver and heart also present 
after the recovery period though they were reduced in severity.  
Renal changes observed in the male and female rats and cardiomyopathy in the heart in female rats 
only at 675 mg/kg bw/day were considered adverse. Haematological changes observed at 225 and 675 
mg/kg bw/day were also considered adverse as they were dose related and red cells changes were also 
present after recovery period of 14 days at the dose of 675 mg/kg bw/day. Therefore the Panel 
established a NOAEL of 75 mg/kg bw/day. 
6. Application of the Procedure 
6.1. Application of the Procedure to Aliphatic Amines and Amides Substances by the 
JECFA (JECFA, 2008b) 
According to the JECFA five of the substances belong to structural class I and seven to structural class 
III using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded five aliphatic amines and amides substances [FL-no: 16.102, 16.103, 16.104, 
16.105 and 17.035] at step A3 in the JECFA Procedure – meaning that the substances are expected to 
be metabolised to innocuous products (step 2) and concluded that the intakes for all substances are 
below the thresholds for their structural class I (step A3).  
The remaining seven flavouring substances in this group cannot be predicted to be metabolized to 
innocuous products. The estimated daily per capita intakes of these flavouring substances are below 
the threshold of concern (i.e. 90 μg/person per day) for structural class III, and a No Observed Adverse 
Effect Level (NOAEL) exists to provide an adequate margin of safety to the estimated intake as 
flavouring substances (step B4). 
Step B4.  
For N-(1-propylbutyl)-1,3-benzodioxole-5-carboxamide [FL-no: 16.098] (N-(heptan-4-
yl)benzo[d][1,3]dioxole-5-carboxamide), the no-observed-effect level (NOEL) of 20 mg/kg bw per 
day from a 93-day study in rats (Kot, 2005a) provides an adequate margin of safety (> 10 million) in 
relation to the currently estimated level of exposure from its use as a flavouring agent in Europe 
(0.0002 μg/kg body weight (bw) per day) and in the USA (0.002 μg/kg bw per day). 
For N-(2,4-dimethoxy-benzyl)-N'-(2-pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099] (N1-(2,4-
dimethoxybenzyl)-N2-(2-(pyridin-2-yl)ethyl)-oxalamide), the NOEL of 100 mg/kg bw per day from a 
93-day study in rats (Kot, 2005b) provides an adequate margin of safety (> 33 million) in relation to 
the currently estimated level of exposure from its use as a flavouring agent in Europe (0.0002 μg/kg 
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bw per day) and in the USA (0.003 μg/kg bw per day). This NOEL is appropriate for the structurally 
related flavouring agents N1-(2-methoxy-4-methylbenzyl)-N2-(2-(5-methylpyridin-2-
yl)ethyl)oxalamide [FL-no: 16.100] and N1-(2-methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-
yl)ethyl)oxalamide [FL-no: 16.101], because they are also oxalamides and are expected to be 
metabolized by similar pathways. For these structurally related flavouring agents, the NOEL of 100 
mg/kg bw per day provides an adequate margin of safety (500 million) in relation to the currently 
estimated levels of exposure to these flavouring agents in both Europe and the USA (0.0002 μg/kg bw 
per day). 
For N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111], the NOEL of 8 mg/kg 
bw per day for the structurally related substance N-ethyl 2-isopropyl-5-methylcyclohexane 
carboxamide ([FL-no: 16.013] considered in FGE.86) from a 28-day study in rats (Miyata, 1995) 
provides an adequate margin of safety (> 13,000) in relation to the currently estimated level of 
exposure from its use as a flavouring substance in Europe (0.6 μg/kg bw/day). 
For 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] (N-[2-
(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxycinnamic acid amide), the NOEL of 8.36 mg/kg bw per 
day for the structurally related N-nonanoyl-4-hydroxy-3-methoxybenzylamide ([FL-no: 16.006] 
considered in FGE.86) from a 90-day study in rats (Posternak et al., 1969) provides an adequate 
margin of safety (> 400,000) in relation to the currently estimated level of exposure from its use as a 
flavouring agent in the USA (0.02 μg/kg bw per day).  
For N-3,7-dimethyl-2,6-octadienylcyclopropylcarboxamide [FL-no: 16.095], the NOEL of 92 mg/kg 
bw per day from a 28-day study in rats (Merkel, 2005) provides an adequate margin of safety (> 
180,000) in relation to the currently estimated level of exposure from its use as a flavouring agent in 
the USA (0.5 μg/kg bw per day). 
The evaluations of the 12 substances are summarised in Table 3.1: Summary of Safety Evaluation of 
Aliphatic Amines and Amides (JECFA, 2008b). 
6.2. EFSA Considerations  
In the previous version of FGE.94, the Panel agreed with the way the application of the Procedure has 
been performed by the JECFA for nine of the 12 aliphatic and aromatic amines and amides. For the 
other three substances [FL-no: 16.090, 16.095 and 16.111] the Panel did not agree and concluded that 
additional toxicity data are needed before they can be evaluated as a flavouring substance. 
Additional toxicity data have now become available for two substances [FL-no: 16.095 and 16.111]: 
Based on the new data submitted (Bauter, 2011) for N-3,7-dimethyl-2,6-
octadienylcyclopropylcarboxamide [FL-no: 16.095] a NOAEL of 73.3 mg/kg bw/day could be in 
established. When comparing this NOAEL at step B4 in the Procedure to the estimated exposure based 
on the MSDI (61 microgram per capita per day, corresponding to 1 microgram /kg bw/day) an 
adequate margin of safety of 7 × 104 can be calculated. 
Based on the new data submitted (Kirkpatrick, 2011) for N-[(ethoxycarbonyl)methyl]-p-menthane-3-
carboxamide [FL-no: 16.111] a NOAEL of 75 mg/kg bw/day could be in established. When 
comparing this NOAEL at step B4 in the Procedure to the estimated exposure based on the MSDI (37 
microgram per capita per day, corresponding to 0.6 microgram /kg bw/day) an adequate margin of 
safety of 12 × 104 can be calculated. 
For 3-(3,4-dimethoxy-phenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] a 
NOAEL of 8.36 mg/kg bw per day for N-nonanoyl-4-hydroxy-3-methoxybenzylamide ([FL-no: 
16.006] considered in FGE.86) from a 90-day study in rats (Posternak et al., 1969) was used by the 
JECFA to provide an adequate margin of safety (> 400,000). However, the Panel considers that N-
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nonanoyl-4-hydroxy-3-methoxybenzylamide is not sufficiently structurally related to 3-(3,4-
dimethoxy-phenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide  [FL-no: 16.090] to be used as a 
supporting substance. 
Thus the Panel concludes that 11 substances can be considered to be of no safety concern at their 
estimated dietary intake based on the MSDI approach. 
For the remaining substance [FL-no: 16.090], additional toxicity data are needed before it can be 
evaluated as a flavouring substance. 
7. Conclusion 
The JECFA has evaluated a group of 12 flavouring substances consisting of aliphatic amines and 
amides at the 68th meeting. All the JECFA evaluated substances are in the Register, and this 
consideration therefore deals with these 12 substances [FL-no: 16.090, 16.095, 16.098, 16.099, 
16.100, 16.101, 16.102, 16.103, 16.104, 16.105, 16.111 and 17.035]. 
The Panel concluded that no supporting FGE was available for the substances in the present FGE.  
Genotoxicity data from in vitro and in vivo studies were available for seven [FL-no: 16.090, 16.095, 
16.098, 16.099, 16.102, 16.103 and 16.111] of the 12 flavouring substances evaluated by the JECFA 
and the results did not indicate any concern for genotoxicity of the substances in this flavouring group. 
In the previous version of FGE.94 the Panel agreed with the way the application of the Procedure has 
been performed by the JECFA for nine of 12 substances, but for three substances [FL-no: 16.090, 
16.095 and 16.095] no adequate NOAEL were available. Since then 90-day studies have become 
available for [FL-no: 16.095 and 16.111] and NOAELs to provide adequate margins of safety are 
derived. 
For 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] the 
JECFA used a NOAEL from a 90-day study in rats for N-nonanoyl-4-hydroxy-3-methoxybenzylamide 
([FL-no: 16.006] considered in FGE.86) to provide an adequate margin of safety. However, the Panel 
considers this substance not sufficiently structurally related to [FL-no: 16.090] to be used as a 
supporting substance. 
Accordingly, additional toxicity data are needed before [FL-no: 16.090] can be evaluated as a 
flavouring substance. 
For 10 of the 12 substances, use levels have been provided by the Industry. Based on these use levels 
the mTAMDI figures calculated for nine substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.102, 
16.103, 16.104, 16.111 and 17.035] are above the threshold of concern for their structural classes. For 
these substances more reliable data are needed. On the basis of such data the flavouring substances 
should be reconsidered using the Procedure. Following this procedure additional toxicological data 
might become necessary. For the remaining two [FL-no: 16.100 and 16.101] of the 12 substances, use 
levels are needed to calculate the mTAMDIs in order to identify those flavouring substances that need 
more refined exposure assessment. 
In order to determine whether the conclusion for the JECFA evaluated substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
are available for 11 substances [FL-no: 16.095, 16.098, 16.099, 16.100, 16.101, 16.102, 16.103, 
16.104, 16.105, 16.111 and 17.035]. For one substance [FL-no: 16.090] information on the 
stereoisomerism has not been specified sufficiently.  
Thus, for one substance [FL-no: 16.090] the Panel has reservations (additional toxicity data are needed 
and the composition of the stereoisomeric mixture has to be specified). 
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For the remaining 11 substances [FL-no: 16.095, 16.098, 16.099, 16.100, 16.101, 16.102, 16.103, 
16.104, 16.105, 16.111 and 17.035] the Panel agrees with JECFA conclusion “No safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach.     
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TABLE 1: SPECIFICATION SUMMARY  
Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2008c) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments / References 
for specifications 
16.090 
1777 
3-(3,4-Dimethoxy-phenyl)-N-
[2-(3,4-dimethoxyphenyl)-
ethyl]-acrylamide 
O
O
N
H
O
O
O
 
4310 
 
69444-90-2 
Solid 
C21H25NO5 
371.43 
Practically 
insoluble or 
insoluble 
Slightly soluble 
 
127.9 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
Mixture of (Z)- and (E)-isomer 
(EFFA, 2010a). (Flavour 
Industry, 2006v). Composition of 
stereoisomeric mixture to be 
specified. 
Register name to be changed to 
3-(3,4-Dimethoxyphenyl)-N-[2-
(3,4-dimethoxyphenyl)-ethyl]-
acrylamide 
16.095 
1779 
N-3,7-Dimethyl-2,6-octadienyl 
cyclopropylcarboxamide 
N
H
O
 
4267 
 
744251-93-2 
Solid 
C14H23NO 
221.00 
Insoluble 
Soluble 
146 (at 1 hPa) 
53 
IR NMR 
98 % 
n.a. 
n.a. 
 
(Flavour Industry, 2004l). 
CASrn refers to (E) isomer. 
Register name to be changed 
accordingly. 
16.098 
1767 
N-(1-Propylbutyl)-1,3-
benzodioxole-5-carboxamide 
N
H
O
O
O
4232 
 
745047-51-2 
Solid 
C15H21NO3 
263.34 
Insoluble 
Sparingly soluble 
 
116 
IR NMR MS 
99% 
n.a. 
n.a. 
 
(Flavour Industry, 2006z). 
16.099 
1768 
N-(2,4-Dimethoxy-benzyl)-N'-
(2-pyridin-2-yl-ethyl)-
oxalamide 
O
O
N
H
O
H
N
O
N
 
4233 
 
745047-53-4 
Solid 
C18H21N3O4 
343.38 
Insoluble 
Sparingly soluble 
 
123 
IR NMR MS 
99% 
n.a. 
n.a. 
 
(Flavour Industry, 2006z).  
[FL-no: 16.099, 16.100 and 
16.101] should be named by the 
same nomenclature principles. 
 
16.100 
1769 
N1-(2-Methoxy-4-
methylbenzyl)-N2-(2-(5-
methylpyridin-2-
yl)ethyl)oxalamide 
O
N
H
O
H
N
O
N
 
4234 
 
745047-94-3 
Solid 
C19H23N3O3 
341.41 
Insoluble 
Sparingly soluble 
- 
132-133 
IR NMR MS 
99% 
n.a. 
n.a. 
 
(Flavour Industry, 2008b).  
[FL-no: 16.099, 16.100 and 
16.101] should be named by the 
same nomenclature principles. 
16.101 
1770 
N1-(2-Methoxy-4-
methylbenzyl)-N2-(2-(pyridin-
2-yl)ethyl)oxalamide 
O
N
H
O
H
N
O
N
 
4231 
 
745047-97-6 
Solid 
C18H21N3O3 
327.38 
Insoluble 
Sparingly soluble 
- 
128-129 
IR NMR 
99% 
n.a. 
n.a. 
 
(Flavour Industry, 2008b).  
[FL-no: 16.099, 16.100 and 
16.101] should be named by the 
same nomenclature principles. 
16.102 
1772 
2,3,4,5,6-Pentahydroxy-N-(2-
hydroxyethyl)-hexanamide HO
N
H
OH
OH
OH
OH
OH
O
 
4254 
 
686298-93-1 
Solid 
C8H7NO7 
239.22 
Soluble 
Soluble 
 
99-100 
IR NMR MS 
99% 
n.a. 
1.562 
 
Mixture of diastereoisomers 
(EFFA, 2010a). Only one 
diastereomer (2R,3S,4S,5R) 
(Flavour Industry, 2012b). 
Register name to be changed to 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2008c) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments / References 
for specifications 
(2R,3S,4S,5R)-2,3,4,5,6-
Pentahydroxy-N-(2-
hydroxyethyl)hexanamide. 
(Flavour Industry, 2008b). 
16.103 
1774 
(2R)-2-Hydroxy-N-(2-
hydroxyethyl)propanamide HO
N
H
O
OH  
4256 
 
5422-34-4 
Liquid 
C5H11NO3 
133.15 
Soluble  
Moderate 
380 
 
IR NMR MS 
99% 
1.481-1.491 
1.185-1.196 
 
(Flavour Industry, 2008b). 
CASrn refers to the racemate. 
Register name or CASrn to be 
changed accordingly. 
16.104 
1775 
2-[(2-
Hydroxypropanoyl)amino]ethy
l dihydrogen phosphate 
P
O
HO
O
HO
N
H
O
OH  
 
 
782498-03-7 
Solid 
C5H12NO6 
213.13 
Soluble 
Moderate 
 
200 
IR NMR MS 
95% 
n.a. 
1.521 
 
 (Flavour Industry, 2008b; EFFA, 
2006x). 
Racemate (EFFA, 2010a).  
16.105 
1773 
2-[(2,3,4,5,6-
Pentahydroxyhexanoyl)amino]
ethyl dihydrogen phosphate 
P
O
HO
O
HO
N
H
O
OH
OH
OHOH
OH  
4255 
 
791807-20-0 
Solid 
C8H18NO10P 
319.21 
Soluble  
Moderate 
 
130 
IR NMR MS 
95% 
n.a. 
1.76 
 
(Flavour Industry, 2008b; EFFA, 
2006x). 
CASrn refers to the 
(2R,3S,4S,5R) isomer. 
Register name to be changed 
accordingly. 
16.111 
1776 
N-[(Ethoxycarbonyl)methyl]-
p-menthane-3-carboxamide 
O
H
N
O
O
4309 
 
68489-14-5 
Solid 
C15H27NO3 
269.38 
Practically 
insoluble 
Soluble 
151 (2.7 hPa) 
80-82 
IR NMR MS 
99% 
n.a. 
n.a. 
 
(Flavour Industry, 2007h). 
CASrn refers to the (1R,2S,5R) 
isomer. 
Register name to be changed 
accordingly. 
17.035 
1771 
4-Amino-butyric acid H2N
OH
O  
 
 
56-12-2 
Solid 
C4H9NO2 
103.12 
Slightly soluble 
Practically 
insoluble 
 
200 
IR NMR MS 
100 % 
n.a 
n.a. 
 
(Flavour Industry, 2006u). 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95%  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2: GENOTOXICITY DATA  
Table 2.1: Summary of Genotoxicity Data of Aliphatic and Aromatic Amines and Amides Evaluted by the JECFA (JECFA, 2008b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vitro 
16.098 
1767 
 
N-(1-Propylbutyl)-1,3-benzodioxole-5-
carboxamide 
N
H
O
O
O
 
Reverse mutationa S. typhimurium TA98, 
TA100, TA1535 and 
TA1537   
0, 21, 62, 190, 560, 1670 or  
5000 µg/plateb   
 
Negativec (Zhang, 2004a) 
Reverse mutationa E. coli   
WP2uvrA   
0, 21, 62, 190, 560, 1670 or  
5000 µg/plateb   
Negativec (Zhang, 2004a) 
Chromosomal 
aberration 
Chinese hamster ovary cells 0, 21, 62, 190, 560, 1670 or  
5000 µg/ml  
Negativec (Zhang, 2004b) 
16.099 
1768 
N-(2,4-Dimethoxy-benzyl)-N'-(2-pyridin-
2-yl-ethyl)-oxalamide O
O NH
O
HN
O
N
 
Reverse mutationa S. typhimurium TA98, 
TA100, TA1535 and 
TA1537   
 
0, 21, 62, 190, 560 or 1670  
 µg/plate 
Weakly 
positive/negativec,
d 
(Zhang, 2005a) 
Reverse mutationa E. coli   
WP2uvrA   
 
0, 21, 62, 190, 560, 1670 or  
5000 µg/plate 
Negativec (Zhang, 2005a) 
Chromosomal 
aberration 
Chinese hamster ovary cells 0, 21, 62, 190, 560, 1670 or  
5000 µg/plate 
Negativec (Zhang, 2005b) 
16.102 
1772 
2,3,4,5,6-Pentahydroxy-N-(2-
hydroxyethyl)-hexanamide    
HO
HO
HO
HO
OH
HN
O
OH
 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535 and 
TA1537   
0, 3,e 10,e 33,e 100, 333, 
1000,  3330 or 5000 
µg/plate    
Negativec (Verspeek-Rip, 2004a) 
Reverse mutation E. coli   
WP2uvrA   
 
0, 3, 10, 33, 100, 333, 
1000,  3330 or 5000 
µg/plate   
 
Negativec (Verspeek-Rip, 2004a) 
16.103 
1774 
(2R)-2-Hydroxy-N-(2-
hydroxyethyl)propanamide    
H
N
OH
O
OH
 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535 and 
TA1537   
 
0, 3,e 10,e 33,e 94, 310, 940,  
3140 or 4720 µg/plate   
 
Negativec (Verspeek-Rip, 2004b) 
Reverse mutation E. coli   
WP2uvrA   
0, 3, 10, 33, 94, 310, 940,  
3140 or 4720 µg/plate   
Negativec (Verspeek-Rip, 2004b) 
16.090 
1777 
3-(3,4-Dimethoxy-phenyl)-N-[2-(3,4-
dimethoxyphenyl)-ethyl]-acrylamide 
O
O
N
H
O
O
O
Reverse mutationa S. typhimurium TA98, 
TA100, TA102, TA1535 
and TA1537   
0, 31.6, 100, 316, 1000 or 
3160 µg/plate 
Negativec (Uhde, 2004b) 
16.111 
1776 
N-[(Ethoxycarbonyl)methyl]-p-menthane-
3-carboxamide 
O
H
N
O
O
 
Reverse mutation S. typhimurium TA98, 
TA100,  TA1535 and 
TA1537  
 
0, 50, 150, 500, 1500, 
2000f, 3000f, 4000f or 5000 
µg/plate 
Weakly positivec,g (Thompson, 2005) 
Reverse mutation E. coli   
WP2uvrA  
0, 50, 150, 500, 1500 or 
5000 µg/plate 
Negativec (Thompson, 2005) 
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Table 2.1: Summary of Genotoxicity Data of Aliphatic and Aromatic Amines and Amides Evaluted by the JECFA (JECFA, 2008b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vivo 
16.098 
1767 
N-(1-Propylbutyl)-1,3-benzodioxole-5-
carboxamide 
N
H
O
O
O
Micronucelus 
induction 
Swiss albino (CD-1) mice 0, 175, 350 or 700 mg/kg 
bwh 
Negative (Pucaj, 2004a) 
16.099 
1768 
N-(2,4-Dimethoxy-benzyl)-N'-(2-pyridin-2-
yl-ethyl)-oxalamide O
O NH
O
HN
O
N
Micronucelus 
induction 
Swiss albino (CD-1) mice 0, 200, 400 or 800 mg/kg 
bwh 
Negative (Pucaj, 2004b) 
16.102 
1772 
2,3,4,5,6-Pentahydroxy-N-(2-
hydroxyethyl)-hexanamide    
HO
HO
HO
HO
OH
HN
O
OH Micronucelus 
induction 
NMRI BR mice 0 or 2000 mg/kg bwi Negative (Buskens, 2004a) 
16.103 
1774 
(2R)-2-Hydroxy-N-(2-
hydroxyethyl)propanamide    
H
N
OH
O
OH Micronucelus 
induction 
NMRI BR mice 0 or 2000 mg/kg bwi Negative (Buskens, 2004a) 
a Plate incorporation assay and preincubation assay. 
b The maximum concentration tested was 1670 μg/plate except for Salmonella typhimurium TA100 in the plate incorporation assay, for S. typhimurium TA98 and TA100 and Escherichia coli WP2uvrA in the preincubation assay without S9 (9000 × 
g supernatant from rat liver) and for S. typhimurium TA98, TA1535 and TA1537 and E. Coli WP2uvrA in the preincubation assay with S9, because of precipitation. 
c With and without metabolic activation. 
d In the plate incorporation assay, S. typhimurium TA1535 tested positive at concentrations of 21, 190 and 1670 μg/plate, but only without S9. In the preincubation assay, S. typhimurium TA100 tested positive only at 62 μg/plate and only with S9. 
e For S. typhimurium TA100 only. 
 f S. typhimuriumTA100 and TA1535 tested without S9 using both plate incorporation and preincubation methods. 
g  Weak incidence of reverse mutation observed in S. typhimurium TA100 and TA1535. All other strains showed no evidence of mutagenicity. 
h Test material administered via single intraperitoneal injection. 
i Test material administered via single gavage dose. 
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Table 2.2: Summary of Additional Genotoxicity Data on N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide Submitted by Industry 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula Test System Test Object  Route Dose Reported Result  Reference  
16.111 
1776 
N-[(ethoxycarbonyl)methyl]-p-
menthane-3-carboxamide 
O
H
N
O
O
 
Mouse Lymphoma L5178Ytk+/- mouse 
lymphoma cells 
Oral 42.03 to 672.5 micrograms/ml 
 
84.06 to 1008.75 micrograms/ml 
 
Negative1
 
Negative2 
(Flanders, 2006) 
Mouse Lymphoma L5178Ytk+/- mouse 
lymphoma cells 
Gavage 10.51 to 504.38 micrograms/ml 
 
42.03 to 672.5 micrograms/ml 
 
Negative1
 
Negative2 
(Flanders, 2006) 
1 Without metabolic activation. 
2 With metabolic activation. 
 
 
Table 2.3: Summary of Additional Genotoxicity Data on N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide Submitted by Industry  
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
16.095 
1779 
 
N-3,7-dimethyl-2,6-octadienyl 
cyclopropylcarboxamide 
N
H
O
 
Reverse mutation S. typhimurium TA97a, 
TA98, TA100, TA1535   
0, 5, 10, 50, 100, 500, 
1000, 2000, 2500 or 5000 
µg/plate  
 
Negative1 (Next Century Incorporated, 2004) 
Reverse mutation E. coli   
WP2uvrA   
0, 50, 100, 500, 1000 or 
2000 µg/plate   
 
Negative1 (Next Century Incorporated, 2004) 
1 With and without metabolic activation. 
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TABLE 3: SUMMARY OF SAFETY EVALUATIONS 
Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2008b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
16.102 
1772 
2,3,4,5,6-Pentahydroxy-N-(2-
hydroxyethyl)-hexanamide HO
N
H
OH
OH
OH
OH
OH
O
 
24 
13 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to 
(2R,3S,4S,5R)-2,3,4,5,6-
Pentahydroxy-N-(2-
hydroxyethyl)hexanamide
. 
16.103 
1774 
(2R)-2-Hydroxy-N-(2-
hydroxyethyl)propanamide HO
N
H
O
OH  
24 
10 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
CASrn refers to the 
racemate. 
Register name or CASrn 
to be changed 
accordingly. 
16.104 
1775 
2-[(2-
Hydroxypropanoyl)amino]ethyl 
dihydrogen phosphate 
P
O
HO
O
HO
N
H
O
OH  
12 
5 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
16.105 
1773 
2-[(2,3,4,5,6-
Pentahydroxyhexanoyl)amino]eth
yl dihydrogen phosphate 
P
O
HO
O
HO
N
H
O
OH
OH
OHOH
OH  
12 
3 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
CASrn refers to the 
(2R,3S,4S,5R) isomer.  
Register name to be 
changed accordingly. 
17.035 
1771 
4-Amino-butyric acid H2N
OH
O  
0.12 
0.1 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
16.090 
1777 
3-(3,4-Dimethoxy-phenyl)-N-[2-
(3,4-dimethoxyphenyl)-ethyl]-
acrylamide 
O
O
N
H
O
O
O
1.2 
1 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) Toxicity data required. Composition of 
stereoisomeric mixture to 
be specified. 
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Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2008b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
16.095 
1779 
N-3,7-Dimethyl-2,6-octadienyl 
cyclopropylcarboxamide 
N
H
O
 
61 
31 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
CASrn refers to (E) 
isomer. Register name to 
be changed accordingly. 
 
16.098 
1767 
N-(1-Propylbutyl)-1,3-
benzodioxole-5-carboxamide 
N
H
O
O
O
0.012 
0.1 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
16.099 
1768 
N-(2,4-Dimethoxy-benzyl)-N'-(2-
pyridin-2-yl-ethyl)-oxalamide 
O
O
N
H
O
H
N
O
N
0.012 
0.2 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
16.100 
1769 
N1-(2-Methoxy-4-methylbenzyl)-
N2-(2-(5-methylpyridin-2-
yl)ethyl)oxalamide 
O
N
H
O
H
N
O
N
0.012 
0.01 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
16.101 
1770 
N1-(2-Methoxy-4-methylbenzyl)-
N2-(2-(pyridin-2-
yl)ethyl)oxalamide 
O
N
H
O
H
N
O
N
0.012 
0.01 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
16.111 
1776 
N-[(Ethoxycarbonyl)methyl]-p-
menthane-3-carboxamide 
O
H
N
O
O
 
37 
34 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
CASrn refers to the 
(1R,2S,5R) isomer. 
Register name to be 
changed accordingly. 
 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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ABBREVIATIONS 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
DTU-NFI Danish Technical University – National Food Institute 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practise 
ID  Identity 
IR  Infrared spectroscopy 
ISS  Istituto Superiore di Sanita 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NMR   Nuclear magnetic resonance 
No  Number 
NOAEL No observed adverse effect level 
NOEL  No observed effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE/NCE Polychromatic eryhtrocyte/normochromatic erythrocyte ratio 
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(Q)SAR (Quantitative) structure-activity relationship 
SCE  Sister chromatid exchange 
SCF  Scientific Committee on Food 
SLRL  Sex-linked recessive lethal mutations 
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA synthesis 
US EPA United States Environmental Protection Agency 
WHO  World Health Organisation  
